Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
20.16
+0.23 (1.15%)
At close: Jan 16, 2026, 4:00 PM EST
20.46
+0.30 (1.51%)
After-hours: Jan 16, 2026, 7:19 PM EST
Zenas BioPharma Employees
Zenas BioPharma had 130 employees as of December 31, 2024.
Employees
130
Change
n/a
Growth
n/a
Revenue / Employee
$115,385
Profits / Employee
-$1,460,762
Market Cap
1.08B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZBIO News
- 2 days ago - Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript - Seeking Alpha
- 12 days ago - Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
- 13 days ago - Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha
- 13 days ago - Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Benzinga
- 13 days ago - Zenas BioPharma's immune disorder drug meets main goal in late-stage trial - Reuters
- 13 days ago - Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire